Amylin and CGRP Head to Head Provocation in Migraine Without Aura Patients

D

Danish Headache Center

Status

Completed

Conditions

Migraine Without Aura

Treatments

Other: Amylin (Pramlintide)
Other: CGRP

Study type

Interventional

Funder types

Other

Identifiers

NCT03598075
H-17035931

Details and patient eligibility

About

Amylin and calcitonin gene related peptide (CGRP) are related to the same peptide family. Both share 16 out of 37 amino acids and can activate each others receptor. CGRP is implicated in migraine pathophysiology but the role of Amylin and its receptor in migraine is not fully clarified.

Full description

Amylin is a peptide hormone that binds to a G-protein coupled receptor (GPCR). amylin was originally found in the pancreas (Beta Cell of Islets of Langerhans) but also shown to be present in the trigeminal ganglion, hind horn ganglia and perivascular nerve fibers. Amylin has many similarities with CGRP. Amylin and CGRP share 16 out 37 amino acids. Both peptides can activate the amylin 1 subtype (AMY1)receptor with high affinity and reported to have more similar physiological and pharmacological effects. In addition, both peptides increase the intracellular concentration of cyclic AMP (cAMP) which has a central role in migraine pathophysiology. The aim of the study is pin point the role of amylin and amylin receptor compare to CGRP in migraine pathophysiology.

Enrollment

36 patients

Sex

All

Ages

18 to 60 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Migraine patients meeting International Headache Society (IHS) criteria for migraine without aura of both sexes, 18-60 year, 50-100 kg.
  • Fertile women should use safe contraception. Fertile women do not include hysterectomized women or women who are postmenopausal for at least 2 years. Safe contraception includes either Intra Uterine Device (IUD), birth control pills, surgical sterilization of the woman or depot progestogen.

Exclusion criteria

  • Tension Type headache for more than 5 days the month on average in the last year.
  • All other primary headaches .
  • Headache later than 48 hours before trial start.
  • Daily intake of any medicine other than oral contraception.
  • Ingestion of any form of medicinal product later than 4 times the plasma half-life substance (on trial day), except for oral contraception.
  • Pregnant or breastfeeding women.
  • Headache on the test day or later than 48 hours prior to administration of trial medicine / placebo
  • Migraine within 5 days before the trial date.

Ancestral information or clinical signs of (on the day of inclusion):

  • Hypertension (systolic blood pressure> 150 mmHg and / or diastolic blood pressure> 100 mmHg)
  • Hypotension (systolic blood pressure <90 mm Hg and / or diastolic blood pressure <50 mmHg)
  • Cardiovascular disease of all kinds, including cerebrovascular disease.
  • Anamnestic or clinical signs of mental illness or abuse.
  • Patients with glaucoma or prostatic hyperplasia
  • Anamnestic or clinical signs of diseases of any kind such as the investigating physician is considered relevant for participation in the trial.

Trial design

Primary purpose

Other

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Triple Blind

36 participants in 2 patient groups

Amylin (Pramlintide)
Other group
Description:
Pramlintide intravenous infusion 120 micrograms over 20 minutes
Treatment:
Other: Amylin (Pramlintide)
CGRP
Other group
Description:
CGRP intravenous infusion 30 micrograms over 20 minutes
Treatment:
Other: CGRP

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems